Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Curasan–SEVERAL: investment, 201410 capital increase w subscription rights €1.5m 2014-10-01
SAW Instruments–NanoTemper: investment, 201410 acquisition by NanoTemper Technologies GmbH 2014-10-01
OSE Pharma–SEVERAL: investment, 201409–201503 IPO €21.1m at Euronext Paris 2014-09-17
Nobel Biocare–Danaher: investment, 201409–201412 public cash tender offer CHF17/share w total value of $2.2b incl debt assumed + net of cash acquired 2014-09-15
Vexim–LifeSci: public relations, 201409 service existent by LifeSci Advisors 2014-09-08
4SC–Yorkville Group: credit, 201409 second tranche €500k convertible notes under up to €15m agreem from 2/14 w YA Global Master SPV Ltd 2014-09-03
Corgenix Medical–Orgentec: investment, 201409–201503 acquisition of Corgenix for $16m in cash by Orgentec Diagnostika 2014-09-01
Ipsen–MHH: rec botulinum neurotoxin, 201409– collab RnD with Thomas Binz at Institute for Physiological Chemistry at MHH 2014-09-01
i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg 2014-08-01
Riboxx–SEVERAL: investment, 201407–201501 crowdfunding €1m via Seedmatch 2014-07-30
Boehringer–Hikma: investment, 201407– acquisition of US generic injectiables business Bedford Laboratories by Hikma from BI 2014-07-28
Metrohm–Waters: chromatography s/w, 201407– collab product integration Empower CDS now can control Metrohm IC systems 2014-07-17
Paion–Pharmascience: investment, 201407 private placement €4m with 1.27m new shares €3.15/share to Pharmasience Intl Ltd 2014-07-17
Geisinger–Indivumed: tissue bank, 201407– collab to create cancer research biobanks at Geisinger + Indivumed 2014-07-15
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie 2014-07-01
GeneWeave–SEVERAL: investment, 201407 financing round Series B $12m from Decheng Capital + Claremont Creek Ventures + XSeed Capital 2014-07-01
GW Pharmaceuticals–SEVERAL: investment, 201406 public offering $126.3m with 1.455m ADSs at $86.83/ADS at Nasdaq 2014-06-25
CytoTools–Instinctif Partners: public relations, 201406 service existent by Instinctif Partners 2014-06-23
CytoTools–SEVERAL: investment, 201406 capital increase €1.7m of CytoPharma GmbH incl €0.3m from >40% owner CytoTools 2014-06-23
Paion–SEVERAL: investment, 201406–201407 capital increase €46.26m placement of 18.5m new shares €2.5/share 2014-06-18
Genkyotex–Halsin Partners: public relations, 201406 service existent by Halsin Partners 2014-06-11
B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania 2014-06-01
Saab–Bruker: analytical instruments, 201406–201511 supply chemical detectors for Saab AWR system delivered to client in Kuwait 2014-06-01
Euprotec–Evotec: investment, 201405 acquisition 100% for £1.9m cash upfront + deferred business performace-based payment 2014-05-28
Neuway Pharma–SEVERAL: investment, 201405 financing round Series A €2.7m led by Wellington Partners 2014-05-25
Neuway Pharma–Wellington Partners: investment, 201405 financing round Series A totalling €2.7m led by Wellington Partners 2014-05-25
Locate Therapeutics–Heraeus: investment, 201405 undisclosed investment €na by Heraeus 2014-05-09
Lophius–SEVERAL: investment, 201405 financing round €2m VRD GmbH + S-Refit + another existing investor 2014-05-08
Novartis–Ophthotech: pegpleranib, 201405– excl license + commercialisation agreem outside of US 2014-05-01
CytoTools–SEVERAL: investment, 201404 capital increase €2.3m of DermaTools Biotech GmbH from mother CytoTools + existing investor 2014-04-28
Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW 2014-04-15
Piqur Therapeutics–SEVERAL: investment, 201404 financing round Series A extension CHF18m led by Versant Ventures with CHF11m 2014-04-08
Piqur Therapeutics–Versant Ventures: investment, 201404 financing round Series A extension totalling CHF18m incl CHF11m from Versant Ventures 2014-04-08
Roche–Oryzon Genomics: LSD1 inhibitors, 201605–201707 collab extension developm of ORY-1001 TERMINATED 7/17 2014-04-07
Qiagen–SEVERAL: credit, 201403–2019 convertible notes $430m at 0.375% 2014-03-12
Qiagen–SEVERAL: credit, 201403–2021 convertible notes $300m at 0.875% to repay outstanding $291m notes due 2026 2014-03-12
4SC–Yorkville Group: credit, 201403 first tranche €500k convertible notes under up to €15m agreem from 2/14 w YA Global Master SPV Ltd 2014-03-04
OPI (CH)–OSE Pharma: investment, 201403 acquisition of assets of OPI SA (Geneva) incl rights to Memopi technology 2014-03-01
Evolva–SEVERAL: investment, 201402–201403 private placement CHF42.5m with 27m+5.5m new shares CHF1.37/share 2014-02-25
Amal Therapeutics–Boehringer: investment, 201402 seed funding round from Boehringer Ingelheim Venture Fund + HTGF 2014-02-20
Amal Therapeutics–High-Tech Gründerfonds: investment, 201402 seed funding round from Boehringer Ingelheim Venture Fund + HTGF 2014-02-20
Centogene–OMERS (CA): investment, 201402 acquisition of Centogene’s Canadian business by LifeLabs 2014-02-19
Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
Synaffix–SEVERAL: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital 2014-02-18
MyoPowers–Truffle Capital: investment, 201402 existent investment listed on Truffle web site 2014-02-12
Symetis–Truffle Capital: investment, 201402 existent investment listed on Truffle web site 2014-02-12
Piqur Therapeutics–SEVERAL: investment, 201401 financing round Series A private placement to new + existing investors 2014-01-21
Biofrontera–SEVERAL: investment, 201401–201402 capital increase €15.3m net with 4.4m news shares 2014-01-20
BPCE–SEVERAL: investment, 201401 launch €120m Seventure Health for Life Capital Fund incl investors Danone + Tereos + Tornier + Natixis + Unigrains 2014-01-20
Aettis–Medigene: investment, 2014 spin-off of Aettis from Catherex with Medigene receiving 39% shareholding in Aettis 2014-01-01
CeeTox–Cyprotex: investment, 201401 acquisition of assets + business of CeeTox by Cyprotex 2014-01-01
Electrochaea–SEVERAL: investment, 2014 financing round Series A 2014-01-01
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon 2014-01-01
Mestex–SEVERAL: investment, 2014 1st financing round 2014-01-01
Padlock Therapeutics–Evotec: drug discovery services, 201401–201412 collab to deliver multiple PAD inhibitor development candidates 2014-01-01
Peqlab–VWR International: investment, 2014 acquisition of Peqlab Biotechnologie GmbH inkl Clemens GmbH by VWR 2014-01-01
Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy 2014-01-01
Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m 2014-01-01
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR 2014-01-01
Tusk Therapeutics–Droia Ventures: investment, 201809 existent majority shareholder + founding investor Droia Oncology Ventures 2014-01-01
Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors 2013-12-19
Eloxx Pharmaceuticals–SEVERAL: investment, 201311 initial closing of 1st financing round with Roche + Pontifax 2013-11-21
GAS GmbH–Imspex: investment, 201311 acquisition of 100% of G.A.S. by Imspex Diagnostics Ltd 2013-11-20
Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund 2013-11-18
m2p-labs–SEVERAL: investment, 201311 3rd financing round Fidura Private Equity Fonds + HTGF 2013-11-01
Polymedco–Epigenomics: molecular diagnostics, 201310– collab joint commercialisation of Epi proColon test in North America 2013-10-02
Labfolder–SEVERAL: investment, 201310 seed financing round € high 6-digit incl Vogel Ventures + VC Fonds Technologie Berlin 2013-10-01
ArcherDX–Enzymatics: investment, 201309 acquisition up to $50m in cash + equity + milestones 2013-09-06
Piqur Therapeutics–SEVERAL: investment, 201309 private placement (third seed financing round) 2013-09-05
Gardner Denver–KKR: investment, 201307 acquisition 100% for $3.9b incl assumption of debt 2013-07-16
Helsinn–Advancell: dermatic, 201307– license ww excl to ATH008 to treat chemotherapy-induced skin damage 2013-07-09
Bruker–3M: MALDI Imaging, 201609– license expansion excl to technique for performing MS analysis on FFPE tissue for pathology 2013-06-04
Allecra Therapeutics–EMBL: investment, 201304 financing round Series A totalling €15m incl co-investor EMBL Ventures 2013-04-18
Allecra Therapeutics–Forbion: investment, 201304 financing round Series A totalling €15m incl co-lead investor Forbion 2013-04-18
Allecra Therapeutics–LCF Rothschild: investment, 201304 financing round Series A totalling €15m incl co-lead investor EdRIP 2013-04-18
Qurient–Max Planck: kinase inhibitors, 201303– license ww excl to Axl kinase inhibitors from LDC 2013-03-12
Harrison Clinical Research–Synteract: investment, 201303 acquisition merger €na of HCR + Synteract into SynteractHCR 2013-03-01
Dynamic Biosensors–SEVERAL: investment, 201302 1st financing round Bayern Kapital + BioM + Extorel + TUM-Fonds 2013-02-01
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management 2013-01-01
BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery 2013-01-01
Boehringer–Qiagen: molecular companion diagnostics, 2013 collab existent incl therascreen EGRF RGQ PCR Kit for Giotrif 2013-01-01
Kaiser Optical Systems–Endress+Hauser: investment, 2013 acquisition by Endress+Hauser 2013-01-01
Roche–Wilex: ADC technology, 2013–201508 collab ATACs with Heidelberg Pharma TERMINATED by Roche 8/15 2013-01-01
Sigma-Aldrich–Olink: research reagents, 2013– distribution of Duolink reagents by Sigma-Aldrich 2013-01-01
PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch 2012-12-04
Piqur Therapeutics–SEVERAL: investment, 201210 seed funding from private investors + KTI 2012-10-01
Novartis–Univ Pennsylvania: T-cell immunotherapy, 201208– collab excl ww RnD alliance to develop CAR cancer therapies 2012-08-06
Roche–AC Immune: therapeutic antibodies, 201206– license excl for anti-Tau program for Alzheimer’s disease to Genentech 2012-06-01
Abionic–SEVERAL: investment, 201205 financing round Series A CHF3.5m from local VCs + business angels 2012-05-01
B Braun–CeGaT: personalised medicine, 201201– collab strategic partnership to expand + internationalise CeGaT’s business 2012-01-31
Bayer–X-Chem: small-molecule drug discovery, 2012– collab research using DEX technology 2012-01-01
Bruker–Univ Geneva: magnet technology, 2012– collab development of superconducting coils for NMR + MRI magnets 2012-01-01
Gilupi–Viroad: investment, 2012 investment in connnection w strategic partnership making Viroad largest shareholder of Gilupi 2012-01-01
JnJ–Phenex: RORgt inhibitors, 2012– collab RnD up to $135m for chronic inflammatory + autoimmune disease w Janssen Biotech 2012-01-01
KBI BioPharma–Selexis: cell line development, 2012– supply service use of cell lines created using SUREtechnology platform by KBI 2012-01-01
Novartis–PeptiDream: drug discovery, 2012– collab strategic alliance using PDPS technology for peptide-based drug discovery 2012-01-01
Qtis/e–Xeltis: investment, 2012 merger of Qtis/e with Xeltis 2012-01-01
next pagenext page 1 2 3 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top